Skip to search formSkip to main contentSkip to account menu

niraparib

Known as: 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 
An inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Niraparib inhibits PARP activity, enhancing the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
There is a vast increase in the number of newly developed anticancer therapeutics, of which marine-derived anticancer drugs and… 
2017
2017
Results: 593 patients were identified from the Edinburgh Ovarian Cancer Database between January 1974 and December 2015. 267… 
2016
2016
Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo… 
2016
2016
Poly-ADP-ribose polymerase 1 (PARP) inhibitors are therapeutically effective in a subset of breast and high-grade ovarian cancers… 
2015
2015
Triple negative breast cancer (TNBC), which comprises 15% of all breast cancers, has a poor prognosis and currently lacks… 
2014
2014
e16531 Background: Niraparib is an oral, potent PARP1/2 inhibitor that induces synthetic lethality in BRCA1/2 deficient and… 
2014
2014
(Lancet Oncol. 15, 852–861; 2014). At an interim analysis, overall survival did not differ between treatment groups. The most…